For example, Immune checkpoint inhibitors (PD1/PD-L1, CTLA-4) have achieved certain success in cancer treatment by block the immune evasion of cancer cells but they are limited in clinical applications mainly due to large individual variations and low therapeutic responses (about 20%) [101,106]. Here, CTLA4 is linked to cancer.